Download our Application Note “Extending half-lives of VHH antibodies”
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable.
Abstract:
Single domain antibodies such as VHH are ideal building blocks for next- generation multi-specific biotherapeutics. They have binding capabilities similar to those of conventional monoclonal antibodies but are typically less immunogenic and can target antigens and epitopes that are considered difficult or intractable for typical antibodies. Their adaptability in formatting and engineering into multiple therapeutic formats, as well as their high thermal stability, make them an essential asset in drug development.
Who should read this:?
Research leaders and principal investigators in biopharmaceutical and academic research centres.
Corporate leaders and business development executives in the biopharmaceutical sector.
